BeOne Medicines Recognized as “Outstanding Global Oncology Company of the Year” at HKCT Business Awards 2026

• BTK Inhibitor: As the company’s first self-developed innovative drug, it holds a significant position in the global market (including Hong Kong), particularly in the field of B-cell malignancies.
• PD-1 Inhibitor: Launched in more than 50 markets worldwide, reaching 1.8 million people. In Hong Kong, it has been approved for six indications, including immunotherapy for lung, esophageal and gastric cancers.
• Next-Generation BCL-2 Inhibitor: Approved for certain lymphoma indications in Mainland China. It has been granted Priority Review by the U.S. Food and Drug Administration, and a marketing application has been submitted in the European Union.

Manufacturing Network Supporting Global Supply

BeOne maintains an integrated chain from R&D to manufacturing and commercialization, supported by production sites in the United States and China designed to help maintain a stable global supply:

• New Jersey, U.S.: A North America biologics hub integrating manufacturing and clinical R&D. The site spans 1.82 million square feet, including a dedicated 400,000-square-foot production facility.
• Suzhou, China (small molecule manufacturing): Supports clinical and commercial-scale production in accordance with applicable FDA, EMA and GMP requirements.
• Guangzhou, China (biologics and ADC manufacturing): A 1.3 million-square-foot facility supporting R&D and production of antibody-drug conjugates (ADCs) and serving as a supply hub for the Greater Bay Area, including Hong Kong.

BeOne has also been recognized by industry organizations for its innovation, including being named one of the “Top 10 Most Inventive” pharmaceutical companies by IDEA Pharma in 2025^[1]. The company will continue to advance programs in hematologic malignancies and solid tumors, with Hong Kong serving as a strategic hub to support the delivery of innovative therapies globally.

1. 2025 Pharmaceutical Innovation and Invention Index, IDEA Pharma

This material is intended for the purpose of communicating disease-related knowledge and cutting-edge medical information to the public and is not intended for promotional or advertising purposes. It does not constitute a promotion or recommendation for any medication or treatment plan, nor can it serve as a substitute for the advice of medical and health professionals. If you have any questions, please consult a medical or health professional.

Hashtag: #BeOneMedicines

https://www.beonemedicines.com/

The issuer is solely responsible for the content of this announcement.

About BeOne Medicines

BeOne Medicines is a global oncology company domiciled in Switzerland, focused on discovering and developing innovative treatments designed to be more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is advancing a diverse pipeline of novel therapeutics through internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to improving access to medicines for more patients. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

About HKCT Business Awards 2026

Organized by the Hong Kong Commercial Times, the HKCT Business Awards is a representative annual event in the Hong Kong business community. It honors companies demonstrating excellence, innovation, and significant contributions to Hong Kong’s economy and society across dimensions including technological innovation and market competitiveness.